Company: DRTSW
Filing Date: 2025-04-28
Form Type: 424B5
Source: 0001213900-25-035799
Chunk: 47

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-04-28
Form: 424B5
Chunk 47
---
 institutions.
U.S. Holders are urged to consult their tax advisors regarding their information reporting obligations, if any, with respect to their
ownership and disposition of our ordinary shares and the significant penalties for non-compliance.

<div align='center'>S-27

PLAN OF DISTRIBUTION</div>

The offering price of the ordinary shares offered
by this prospectus supplement and the accompanying base prospectus has been determined based upon arm’s-length negotiations between
the Investor and us.

We have entered into a securities purchase agreement
directly with the Investor in this offering. A form of the purchase agreement will be included as an exhibit to our Report on Form 6-K
to be filed with the SEC in connection with this offering.

The purchase agreement provides such investors
with certain representations, warranties and covenants, including indemnifications, from us. Our obligation to issue and sell the securities
to the Investor is subject to the closing conditions set forth in the securities purchase agreement, including the absence of any material
adverse change in our business and the receipt of certain opinions, letters and certificates from us or our counsel, which may be waived
by the respective parties. All of the securities will be sold at the offering price specified in this prospectus supplement and, we expect,
at a single closing.

Additionally, pursuant to the terms of the purchase
agreement, on or before the three month anniversary of the closing date (as defined in the purchase agreement), the Investor shall have
the right to nominate two persons to serve as directors on our Board of Directors, subject to approval by our Nominating and Corporate
governance Committee and other customary conditions.

Delivery of the ordinary shares offered hereby
is expected to take place on or about April 28, 2025, subject to satisfaction of certain closing conditions.

We estimate the total expenses that will be payable
by us in connection with the offering described in this prospectus supplement and the accompanying prospectus, will be approximately $0.1
million, which includes our estimated legal and accounting and printing costs.

The Investor will also be informed of the date
and manner in which they must transmit the purchase price for their ordinary shares purchased. Our obligation to issue and sell ordinary
shares is subject to the conditions set forth in the securities purchase agreement, which may be waived by us at our discretion. The Investor’s
obligation to purchase ordinary shares is subject to the conditions set forth in the purchase agreement, which may also be waived. There
is no requirement that any